High Performance Liquid Chromatographic Method for the Determination of Piroxicam, Naproxen, Diclofenac Sodium, and Mefenamic Acid in Bulk Drug and Pharmaceutical Preparations by Dikran, Sarmad Bahjat & Mahmood, Ruaa Moayed
Journal of University of Babylon, Pure and Applied Sciences,Vol.(26), No.(5): 2018 
 
387 
 
High Performance Liquid Chromatographic Method for 
the Determination of Piroxicam, Naproxen, Diclofenac 
Sodium, and Mefenamic Acid in Bulk Drug and 
Pharmaceutical Preparations 
Sarmad Bahjat Dikran                     Ruaa Moayed Mahmood 
 
Chemistry Department, College of Education for Pure Science-Ibin Al-Haitham, University of 
Baghdad 
Ruaa_Moayed@yahoo.com 
   
Abstract 
   A simple accurate and rapid reversed phase high performance liquid chromatographic method has been developed and 
validated for the determination of four nonsteroidal anti-inflammatory drugs;  Piroxicam(PX),  Naproxen(NAP),  
Diclofenac sodium(DCL) and Mefenamic acid(MFNC) in their pure form and different commercial pharmaceutical 
formulation. The separation was performed on a NUCLEODUR® 100-5 C18ec (250 × 4.6 mm i.d.; particle size 5 μm) 
column as stationary phase with a mobile phase comprising of acetonitrile: deionized water acidified with 1% acetic acid 
in gradient mode. The flow rate was 1.5 mL.min-1 at the temperature 35 ºC and detection was carried out at 264 nm. 
Separation has been completed within 8 min. The retention times of Piroxicam, Naproxen, Diclofenac sodium, and 
Mefenamic acid were 4.267 min, 4.785 min, 6.555 min, and 7.683 min respectively. The linearity for Piroxicam was in the 
range of 3–200 μg.mL-1 and for Naproxen and Mefenamic acid was in the range 1-200 μg.mL-1, while for Diclofenac 
sodium was in the range 1.5–200 μg.mL-1. The proposed method was successfully applied for the determination of these 
drugs in their pure form and different pharmaceutical preparations (tablets, capsules, and ampoule) and there is no 
interference with additives.  
Keywords: High performance liquid chromatography, Piroxicam, Naproxen,      Diclofenac sodium, 
Mefenamic acid. 
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Introduction  
 
Piroxicam, Naproxen, Diclofenac sodium, and Mefenamic acid (Figure 1), are nonsteroidal 
anti-inflammatory drugs (NSAID) which display a potent analgesic activity and are effective in 
the treatment of rheumatoid arthritis, osteoarthritis, and other joint diseases. These drugs are 
related to inhibition of cyclo-oxygenase (Cox), a key enzyme of prostaglandin biosynthesis at the 
site of inflammation (1). 
Different analytical methods are reported for estimation of these drugs in pharmaceuticals 
individually or in mixture with other drugs (2-4). Various chromatographic techniques are also available 
in the literature. These include gas-liquid chromatography (5), liquid chromatographic (6), and HPLC (7-
13); however, there is no RP-HPLC method reported for simultaneous determination of the four cited 
drugs. 
The aim of the work is to develop a HPLC method for determination of piroxicam, naproxen, 
diclofenac sodium, and mefenamic acid in mixture of the four drugs in their pure forms and in 
pharmaceutical preparation. 
 
Figure 1. Chemical structures of the studied drugs. 
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Experimental 
Materials and reagents 
 
The solvents which are used (acetonitrile, methanol) were of HPLC grade and analytical grade 
acetic acid supplied from Sigma-Aldrich company (Germany) and water was of HPLC grade 
supplied from Scharlau company (Spain). The investigated samples of piroxicam, naproxen, 
diclofenac sodium, and mefenamic acid were obtained from S.D.I-Iraq. Tablets, capsules, and 
ampule were purchased from local pharmacy. 
Chromatographic system 
The HPLC system was composed of two LC-20AD pumps, an SPD-20A UV-VIS detector, an 
SIL-20AC auto injector, a DGU-20A5 degasser, an CBM-20A system controller, and CTO-20A 
column oven (all from Shimadzu, Kyoto, Japan). An NUCLEODUR® 100-5 C18 ec (250 × 4.6 
mm i.d.; particle size 5 μm) column (MACHEREY-NAGEL Germany) was used for separation. 
The chromatographic and the integrated data were recorded using Shimadzu's LCsolution 
software operated on a Pentium-4 computer system.  
Chromatographic conditions  
Chromatographic separation was achieved using a RP- NUCLEODUR® 100-5 C18 ec 
column. The mobile phase consisted of acetonitrile:deionized water acidified with 1 % acetic acid 
in a ratio (50:50, v/v). It was filtered through a 0.45μm filter, degassed by ultra-sonication for 10 
min before use. A steady flow rate of 1.5 mL.min-1, temperature 35 ºC and injection volume 30 
µL were used to carry out the separation in gradient mode and the detection was made at 264 nm. 
Complete resolution of the peaks with clear baseline was obtained Figure 5. Peak areas and peak 
height were measured for the quantitation of the analytes. 
Preparation of drug standard, formulation and matrix solutions 
Standard stock solution of each drugs was made in methanol containing 1000µg.mL-1. A mixture of 
four drugs containing 10µg.mL-1 was prepared and was stored at 4 ºC and protected from light. 
The solutions of formulation were prepared in a similar way. Ten weighed tablets of each 
formulation were finely powdered (or the content of ten capsules) and homogenized in a mortar. 
An amount equivalent to content of the active ingredient per tablet (or capsule) was taken into a 
10 mL volumetric flask, dissolved in methanol, ultra-sonicated for approximately 10 min, and 
made up to the mark with methanol. The supernatant liquid was collected and filtered through a 0.45-
micron filter for use and three concentrations 200, 100 and 10 µg.mL-1 were prepared for each preparation 
by serial dilution. On the other hand, 1000 µg.mL-1 solution of DCL was prepared by diluting the 
content of an ampoule (75mg/3mL) with methanol, and other working solutions were prepared by 
serial dilution with methanol. All solutions were stored at 4 ºC and protected from light. 
Method validation 
The proposed method was validated with respect to suitability of the method, linearity, 
accuracy, and precision, the limit of detection (LOD) and, limit of quantification (LOQ).  
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Suitability of the method  
The column efficiency, resolution, and selectivity were calculated for the standard solutions. 
The values obtained demonstrated the suitability of the system for analysis of these drugs. 
Linearity 
The linearity of the response, expressed as peak area, to different concentrations of PX, NAP, 
DCL, and MFNC was studied and the data were subjected to statistical analysis using a linear-
regression model. 
Accuracy 
Accuracy of the method was performed by estimating the relative error percent of the method 
experiments. The relative error percent of PX, NAP, DCL, and MFNC were determined for three 
replicates by spiking each at three different levels 10, 100, and 200 μg.mL-1. Similarly, recovery 
studies were carried out for the four drugs by calculating the recovery (n=3) at three different levels of 
drug concentration. 
Precision  
Drug solutions were prepared at different concentrations, and precision of the method was 
studied using repeatability. Repeatability was the intra-day variation in assay obtained at different 
concentration levels of PX, NAP, DCL, and MFNC and expressed in terms of relative standard 
deviation (RSD) calculated for each day.  
LOD and LOQ 
LOD and LOQ represent the concentration of the analyte that would yield signal-to-noise ratios of 3 for 
LOD and 10 for LOQ, respectively. LOD and LOQ were determined by measuring the magnitude of 
analytical background, i.e. by injecting a series of blank solutions (n=5) and calculating the signal-to-noise 
ratio for each compound. 
Method development 
 
A mixture of PX, NAP, DCL, and MFNC was subjected to separation by RP-HPLC on C18 columns. 
Initially, deionized water acidified with acetic acid were tried using methanol and acetonitrile as organic 
modifiers. However, the compounds exhibited incomplete separation and a characteristic tailing on all 
columns. This could be due to their ability to form strong hydrogen bonding with the residual silanols of the 
C18 materials. To overcome these problems several mobile phase compositions, concentration of acetic acid, 
flow rates, isocratic and gradient modes were tried. Moreover, to minimize the peak tailing, the column 
temperature was increased (25 ºC – 50 ºC).     
Results and discussion 
 
The present study aimed to develop a chromatographic method for separation and 
determination of PX, NAP, DCL, and MFNC Figure 1. The HPLC conditions were optimized by 
studying the effects of concentration of organic modifier, concentration of acetic acid, mobile 
phase flow rate and column temperature. 
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Effect of organic modifier 
 
Isocratic mode elution using deionized water acidified with 1% acetic acid and methanol or acetonitrile as 
organic modifiers on an RP- NUCLEODUR® 100-5 C18 ec (250 mm × 4.6 mm) column maintained at 25 
ºC. Using acetonitrile as a modifier gave a reasonably accepted separation. This could be attributed little 
ability of acetonitrile to accept weak hydrogen bond than methanol and a high dipole moment which enables 
him to participate in selective dipole-dipole interaction with certain solutes (14). Moreover, the mobile phase 
becomes less viscosus than the corresponding methanol/water mixtures; It thus enables faster flow rates 
develops faster separation methods (15). Therefore, acetonitrile was selected as an organic modifier. Further 
studies were carried out to determine the effect of acetonitrile concentration on separation. Several proportions 
were tried, and the degree of the separation was followed by checking the values of chromatographic 
parameters in addition to the shape of chromatographic bands. It was found that increasing the percent of 
acetonitrile, above 50%, leads to decrease in the analysis time as well as an increase in the peak heights, but 
no-good resolution of peaks was observed. The study shows a significant difference in the separation of the 
investigated drugs when a mobile phase composition was varied from 50:50 water acidified with 1% acetic 
acid: methanol to 50:50 water acidified with 1% acetic acid: acetonitrile Table 1. 
 
Table 1. The effect of organic modifier on efficiency and retention factors 
Organic modifier 
(%) 
k' N 
PX NAP DCL MFNC PX NAP DCL MFNC 
48 2.71 3.38 7.89 13.51 3085.2 3897.7 6441.5 8997.2 
50 2.41 3.03 6.79 11.40 3340.3 4520.5 6742.6 9639.4 
55 1.92 2.17 4.50 7.40 3506.5 4075.4 6600.7 9189.1 
60 1.54 1.54 2.98 4.78 2774.5 2774.5 6419.6 8966.9 
65 1.23 1.23 2.18 3.45 1997.5 1997.5 6362.9 8729.2 
70 0.95 1.06 1.60 2.49 1611.7 2942.7 6091.6 8643.0 
75 0.71 0.90 1.22 1.86 1597.4 1819.5 5650.4 7825.1 
85 0.52 0.69 0.77 1.12 1146.9 4473.5 4936.8 6960.4 
90 0.47 0.64 0.64 0.92 1808.0 2033.1 2033.1 6033.7 
95 0.44 0.55 0.55 0.78 2391.8 2180.3 2180.3 3543.5 
Concentration of Acetic acid 
 
The effect of the concentration of CH3COOH on the separation was studied by maintaining all 
other factors constant. Figure 2 shows that there is no significant effect of the concentration of 
acetic acid on separation of peaks as well as run analysis when the concentration of the acid is 
varied from 0.25 % to 1.0%. . Hence, 1% acetic acid was used in all the subsequent experimental 
work.  
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Figure 2. The effect of acetic acid percentage on retention factors (k'). 
Effect of Flow rate of the mobile phase 
Different flow rates of mobile phase ranged between 0.8 to 1.7 mL.min-1 were tried to choose the 
optimum flow rate that achieve complete analysis within a short time and reasonable sensitivity and high 
column efficiency. Results in Figure 3 indicated that the suitable flow rate of the mobile phase for 
separation of the studied drugs is 1.5 mL.min-1. 
 
Figure 3. The effect of flow rate on retention factors (k'). 
Effect of temperature 
 
The column was maintained at different temperatures ranging from 25 ºC – 50 ºC in a thermostated 
oven. Generally increasing column temperature in RP- chromatography decreases the retention times of 
the separated bands and increases column efficiency by decreasing mobile phase viscosity, which in turn 
lowering the column head pressure. Table 2 show the values of retention times, retention factors, 
selectivity, efficiency N and resolution Rs for each drug at different temperature. Finally, separation was 
carried out by maintaining the column at 35 ºC. At this temperature a good shape and resolution of the 
separated bands of the drugs were obtained Figure 4.  
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Figure 4. Overlaid chromatogram of four drugs at different temperature. 
Table 2. The Effect of Temperature on retention times, retention factors, selectivity, efficiency, 
and resolution in Optimized Conditions. 
Temperature (⁰ C) Drug tR k` α N Rs 
25 
PX 4.495 2.22 1.28 5012.12 3.13 
NAP 5.356 2.84 7111.67 
2.24 10.70 
DCL 10.275 6.37 8883.69 
1.68 8.98 
MFNC 16.332 10.72 9890.04 
30 
PX 4.411 2.13 1.26 4855.40 2.97 
NAP 5.205 2.69 6923.21 
2.24 10.62 
DCL 9.915 6.03 8547.26 
1.68 8.93 
MFNC 15.707 10.13 9452.04 
35 
PX 4.304 2.03 1.28 4656.96 3.05 
NAP 5.010 2.59 6679.63 
2.22 10.46 
DCL 9.412 5.75 8326.32 
1.67 8.82 
MFNC 14.804 9.62 9108.47 
40 
PX 4.184 1.97 1.22 4382.69 2.48 
NAP 4.796 2.41 6579.25 
2.20 10.27 
DCL 8.869 5.30 7981.10 
1.67   8.70 
MFNC 13.844 8.83 8649.80 
45 
PX 4.067 1.86 1.20 4173.08 2.23 
NAP 4.593 2.23 6181.74 
2.18 10.05 
DCL 8.344 4.86 7714.23 
1.66 8.57 
MFNC 12.917 8.08 8265.55 
50 
PX 3.964 1.83 1.18 4023.42 1.99 
NAP 4.415 2.15 5826.56 
2.15 9.84 
DCL 7.883 4.62 7292.59 
1.65 8.44 
MFNC 12.100 
7.62 7753.21 
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Development of the gradient HPLC method 
Although, a reasonable separation of the cited drugs was achieved via isocratic elution, 
gradient elution was tried to decrease the analysis time and improve the resolution since mode of 
elution increase quasi-efficiency of the column (16).  
   Figure 5 shows that quality separations in terms of, resolution, reasonable run time, and peak 
symmetry were obtained using the gradient steps shown in Table 3. 
 
Figure 5. Chromatogram of mixture of four drugs (10 µg.mL-1) in gradient elution system. 
Table 3. Gradient elution program for separation of four drugs using RP-HPLC. 
Time (min) Module Action Value 
0.0 Pumps Acetonitrile Conc 0 
8.0 Pumps Acetonitrile Conc. 100 
8.1 Controller stop  
Validation 
System suitability 
   The column efficiency, resolution, and selectivity were calculated for the standard solutions and 
the results are expressed in Table 4. The values obtained demonstrated the suitability of the 
system for analysis of these drugs. 
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Table 4. System suitability Data. 
System suitability parameter PX NAP DCL MFNC 
Retention time (tR), min 4.259 4.774 6.544 7.672 
Retention factors (k`) 2.01 2.38 3.63 4.43 
Theoretical plate number (N) 5504.06 10817.13 27406.05 37556.34 
Resolution factor (Rs) 2.44 9.35 6.62 
Selectivity (α) 1.18 1.53 1.22 
Linearity, LOD, and LOQ 
 
   The peak areas of PX, NAP, DCL, and MFNC were linear with respect to the concentrations 
over the range of 3-200 µg.ml-1 for PX, 1.5-200 µg.ml-1 for DCL and 1-200 µg.ml-1 for NAP and 
MFNC Figure 6. Statistical analysis of data were carried out using a linear-regression model. The 
linear regression equations and determination coefficients (r2) indicate good linearity. The limit of 
detection (LOD) and limit of quantification (LOQ) were calculated from the linearity curve and 
are shown in Table 5. 
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Figure 6. Calibration graphs, concentration (µg.ml-1) vs. peak area for PX, NAP, DCL, and 
MFNC. 
 
Table 5. Calibration Data. 
Drug 
Linearity 
range 
(μg.mL-1) 
Regression 
equation 
r
2
 Slop Intercept 
LOD 
(μg.mL-1) 
LOQ 
(μg.mL-1) 
PX 3-200 y=12913 x-29036 0.9988 12913 29036 0.281 0.926 
NAP 1-200 y=12087 x-11117 0.9996 12087 11117 0.300 0.989 
DCL 1.5-200 y=14742 x-15862 0.9995 14742 15862 0.246 0.811 
MFNC 1-200 y=14440 x-13377 0.9995 14440 13377 0.251 0.828 
Analysis of bulk drugs and formulations 
The contents of PX, NAP, DCL, and MFNC obtained from the measurement of their 
concentrations in different commercial tablet, capsule, and ampul dosage are shown in Figure 7 
and Table 6. The results show good correlation between the declared and determined values of 
cited drugs for all analyzed samples, which indicates a reasonable efficacy and selectivity of the 
method used. 
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Figure 7. Typical overlaid chromatogram of four drugs in different pharmaceutical preparations 
at 200,100 and 10 µg.mL-1. 
 
Table 6. Application of the method to the drugs concentration measurements in different 
pharmaceutical preparations. 
Sample 
Conc. taken 
(µg.mL
-1
 ) 
Weight* found 
(mg/formulation) 
Recovery 
 % 
RSD  
% 
PX capsule 
20mg 
10 20.89 104.3 0.1224 
100 20.17 100.7 0.1529 
200 20.82 104.2 0.0681 
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NAP tablet 
500mg 
10 485.19 97.0 0.0442 
100 483.52 96.7 0.1075 
200 481.52 96.3 0.3964 
DCL tablet 
50mg 
10 53.98 107.9 0.2256 
100 50.91 101.8 0.1907 
200 52.71 105.4 0.2811 
DCL ampoule 
75mg/3mL 
10 73.02 97.4 0.1258 
100 68.69 91.6 0.3327 
200 73.41 97.9 0.2884 
MFNC tablet 
500mg 
10 489.28 97.9 1.2276 
100 475.92 95.2 0.6002 
200 489.42 97.9 0.3018 
MFNC 
capsule 
250mg 
10 245.51 98.2 0.3401 
100 249.21 99.7 0.1214 
200 246.86 98.7 0.3880 
*Average of three determinations. 
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